Cardioprotection by vanadium compounds targeting Akt-mediated signaling

Md Shenuarin Bhuiyan, Kohji Fukunaga

Research output: Contribution to journalReview articlepeer-review

58 Citations (Scopus)


Treatment with inorganic and organic compounds of vanadium has been shown to exert a wide range of cardioprotective effects in myocardial ischemia/reperfusion-induced injury, myocardial hypertrophy, hypertension, and vascular diseases. Furthermore, administration of vanadium compounds improves cardiac performance and smooth muscle cell contractility and modulates blood pressure in various models of hypertension. Like other vanadium compounds, we documented bis(1-oxy-2-pyridinethiolato) oxovanadium (IV) [VO(OPT)] as a potent cardioprotective agent to elicit cardiac functional recovery in myocardial infarction and pressure overload-induced hypertrophy. Vanadium compounds activate Akt signaling through inhibition of protein tyrosine phosphatases, thereby eliciting cardioprotection in myocardial ischemia / reperfusion-induced injury and myocardial hypertrophy. Vanadium compounds also promote cardiac functional recovery by stimulation of glucose transport in diabetic heart. We here discuss the current understanding of mechanisms underlying vanadium compound-induced cardioprotection and propose a novel therapeutic strategy targeting for Akt signaling to rescue cardiomyocytes from heart failure.

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalJournal of Pharmacological Sciences
Issue number1
Publication statusPublished - 2009


  • Bis(1-oxy-2- pyridinethiolato) oxovanadium (IV) [VO(OPT)]
  • Myocardial hypertrophy
  • Myocardial ischemia/reperfusion
  • Protein kinase B/Akt

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Cardioprotection by vanadium compounds targeting Akt-mediated signaling'. Together they form a unique fingerprint.

Cite this